Search Results for 'Biosimilars'

---

Contract Service Directory Companies

View All Buyers Guide Companies »

---

Contract Service Directory Categories

View All Categories »

---

• Bio News | Biosimilars
  

  Know the Challenges of Biosimilar Manufacturing

  Best Practices for a Competitive Market

  Jerry Martin, Pharmaceutical and Life Sciences Consultant to PMMI, and, Dr. Michiel Ultee, Principal, Ulteemit BioConsulting, LLC 04.11.18
  

  ---

• Biosimilars
  

  Indian Generic Firms Expand Biosimilar Portfolios

  With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India

  S. Harachand, Contributing Editor 05.09.17
  

  ---

• Biosimilars
  

  CMOs & Biosimilars Mfg. in the U.S.

  Biosimilars are moving from novel opportunity to mainstream product

  Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17
  

  ---

• Biosimilars | Clinical Trials | Formulation Development
  

  Critical Steps for Biosimilar Assessment

  Establishing “finger-print like” biosimilarity prior to the clinic

  Fiona Greer, SGS 05.05.16
  

  ---

• Biosimilars | Clinical Trials | Process Development
  

  Biosimilars Outsourcing and Capacity

  CMOs to play important but uncertain role in biosimilars manufacturing

  Ronald A. Rader and Eric S. Langer, BioPlan Associates 05.05.16
  

  ---

• Biosimilars | Clinical Trials | Risk Management
  

  Growth of Biosimilars: Implications for Safety and Risk Management

  Global biologics market will expand to $250 billion annually by 2020, with biosimilars and non-original biologics commanding 4-10% of that market

  Suhasini Sharma, Sciformix Corporation 09.11.15
  

  ---

• Bioassay Development | Biologics, Proteins, Vaccines | Biosimilars | Clinical Trials | Drug Development | GMPs/GCPs | Inspections | Methods Development | Process Development | Regulatory Affairs | Supply Chain | Toxicology | Validation
  

  Challenges in Global Biosimilar Development: A Regulatory Perspective

  More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry.

  Patricia Hurley, Joan Boren and Costantino Congiatu, PPD 06.02.15
  

  ---

• Biosimilars

  Biosimilars and Biobetters: From Basic Similarity to Simplified Innovation

  Everyone talks about biosimilarity, but it’s clarifying the differences between biosimilars, biobetters and me-too products that will be critical to biological innovation and pricing

  Fereshteh Barei, Dauphine University 06.18.14
  

  ---

• Biosimilars | Clinical Trials | Logistics | R&D

  Biosimilars and Cold Chain Issues

  Good distribution practices will impact follow-on biologics

  Kevin O'Donnell 03.04.09
  

  ---